Hetero-substituted cyclic lactone analogues and uses thereof

Patent metadata

Field	Value
Publication number	US-11021488-B2
Application number	US-201916523687-A
Country	US
Kind code	B2
Filing date	Jul 26, 2019
Priority date	Nov 5, 2015
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.

First claim

What is claimed is:

1. A method for inhibiting growth of a cancer cell derived from a blood cancer, the method comprising contacting the cancer cell with an effective amount of a composition comprising a compound of Formula (II) or a pharmaceutically acceptable salt thereof:

wherein:
R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl, wherein one or more of R 1 , R 2 and R 3 comprise a substituted hydrocarbyl comprising an atom selected from the group consisting of fluorine, oxygen, nitrogen, chlorine, bromine, and iodine;
R 4 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;
is a single or double bond; and
is a SL ring structure, minus the lactone ring, from the class of guaianolides.

2. The method of claim 1 , wherein R 4 and R 5 are independently selected from the group consisting of hydrogen, —OCOCH 3 , alkoxy, hydroxyalkyl, carbonylalkyl, carbonyl substituted alkyl, carbonylalkoxy, carbonylaminoalkyl, alkyl, substituted alkyl, ester, substituted ester, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl.

3. The method of claim 1 , wherein the lactone ring does not contain a double bond, comprises an α-methylene group and R 4 and R 5 are hydrogen.

4. The method of claim 1 , wherein the lactone ring contains a double bond, does not comprise an α-methylene group, R 4 is hydrogen and R 5 is selected from the group consisting of —OCOCH 3 , alkyl, substituted alkyl, ester and substituted ester.

5. The method of claim 1 , wherein the lactone ring contains a double bond, does not comprise an α-methylene group, R 4 is hydrogen and R 5 is OCOCH 3 .

6. The method of claim 1 , wherein the compound of Formula (II) is bahia II.

7. The method of claim 1 , wherein the compound of Formula (II) has an LD 50 in vitro of 2 μM or less.

8. The method of claim 1 , wherein the cancer cell is a leukemic cell.

9. The method of claim 1 , wherein the cancer cell is a cancer stem cell.

10. The method of claim 1 , wherein the cancer cell is in vivo or in vitro.

11. The method of claim 1 , wherein the compound of Formula (II) interacts with Cys-38 of NF-κB.

12. The method of claim 1 , wherein the inhibiting growth is measured as the expression of NF- K B.

13. The method of claim 1 , wherein the blood cancer is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, myelodisplastc syndrome and myeloproliferative neoplasms.

Assignees

• Bioventures Llc
• Univ Cornell
• New York Botanical Garden
• Univ Arkansas

Inventors

• Guzman Monica L
• Compadre Cesar M
• Ordonez Paola E
• Martinez Mariano
• Balick Michael J
• Jones Darin E
• Gaudio Flavio G

Classifications

• C07D493/10 Primary

  Spiro-condensed systems · CPC title

• C07D493/04

  Ortho-condensed systems · CPC title

• C07D493/18

  Bridged systems · CPC title

• C07D493/08

  Bridged systems · CPC title

• C07D307/93

  condensed with a ring other than six-membered · CPC title